R+D+i Projects
Research is a fundamental part of our business
Learn about our research projects
As a biotechnology company, at Dreamgenics we carry out various R&D&I projects with the aim of developing new products and services to offer our customers.
In the same way, we participate together with hospitals and research centers in projects related to human health in which we put our expertise in NGS data analysis at the service of researchers.
Identification of genetic markers with prognostic and therapeutic value in sinonasal tumors using RNA-Seq
This project focuses primarily on the underlying genetics of tumor progression in sinonasal tumors, both in premalignant lesions that progress to invasive carcinomas and in primary tumors that develop recurrences or metastases. The goal will be to identify RNA expression profiles characteristic of each type of tumor studied that can serve as supportive tools to improve the clinical management of patients.
-
Period: 2025–2027 -
Financing: 54.280,69 €
Home monitoring and identification of risk profiles for cisplatin-induced hearing loss
An international project led by the CHU de Montpellier hospital that aims to identify genetic variants predisposing to the development of hearing loss and tinnitus in cancer patients treated with cisplatin. Dreamgenics will participate as the central laboratory, managing the samples and performing sequencing and bioinformatics analysis. The project expects to recruit 750 patients over a three-year period.
-
Period: 2025–2028 -
Financing: 308.400 €
Identification of molecular signatures with prognostic and treatment response value in psoriatic arthritis as a complex disease model.
The goal of this project is to identify prognostic and treatment response biomarkers for psoriatic arthritis using various omics techniques (genotyping, transcriptomics, proteomics, and metabolomics). The advances achieved through this project may subsequently be applied to the study of other spondyloarthropathies and other complex diseases.
-
Period: 2024-2026 -
Financing: 66.587,55 €
Study of molecular profiling in peripheral blood to predict response to ICIs in patients with advanced NSCLC.
Project carried out in collaboration with the Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS). The aim of this project is to determine the molecular bases underlying the response of patients with advanced non-small cell lung cancer (stages III and IV) to treatment with immune checkpoint inhibitors using different omics technologies.
-
Period: 2022-2024 -
Financing: 70.000 €
Development of a platform for analysis, integration and visualization of multi-omics data with clinical application.
This project aims to develop a platform for analysis, integration and visualization of different omics data to overcome the limitations of the isolated whole genome study, so that more valuable information can be obtained from the analysis of different multi-omics data and a broader understanding of the molecular basis of diseases can be achieved.
-
Period: 2022-2024 -
Financing: 21.101,34 €
Development of a platform for the integration of data resulting from different omics analyses and its implementation in the clinic.
Torres Quevedo grant awarded for the development of a project consisting of obtaining the optimal knowledge, carrying out the necessary research, in order to develop a bioinformatics tool to extract all the clinically relevant information that is possible thanks to the integration of all the data from different omics technologies.
-
Period: 2021-2024 -
Financing: 52.077 €
Genetic biomarkers associated with severity in COVID-19
Project led by the Balearic Islands Health Research Institute Foundation (Idisba) to identify genetic variants associated with severity in COVID-19 that can be used as biomarkers in clinical practice. The role of Dreamgenics in this project is the design of the panel of genes to be studied and the bioinformatics analysis of the data from the sequencing.
-
Period: 2020-2021 -
Financing: 25.000 €
Driving innovation in the early detection of childhood hearing loss in the SUDOE area: Towards personalized medicine based on genomic diagnostic tools.
International genetic study led by the Clínica Universidad de Navarra (CUN) for the diagnosis of hearing loss in newborns. The study involves the participation of 8 entities, including Dreamgenics, from 3 different countries and more than 80 professionals involved. All the members of the team have previous experience in genetic work, diagnosis of hearing loss and early detection.
-
Period: 2018-2021 -
Financing: 260.000 €
Bioinformatics platform for whole genome sequencing data analysis and clinical implementation
This project aims to investigate the key aspects that will determine the future development of a bioinformatics tool that is simple and easily interpretable by any physician, regardless of whether or not they have specific training in the emerging field of bioinformatics, and that does not focus solely on the analysis and interpretation of genomic variants in coding regions, as is the case with existing tools.
-
Period: 2017-2020 -
Financing: 68.905,50 €
Design of a framework and development of a prototype for the management and bioinformatics exploitation of genomic data from NGS technologies.
Project aimed at designing a framework based on microservices that would offer an independent scaling of existing bioinformatics analysis algorithms and facilitate the development of new algorithms and functionalities. This framework should allow the bioinformatics analysis, exploitation and visualization of genomic and transcriptomic data from next-generation sequencing (NGS) technologies.
-
Period: 2017 -
Financing: 18.725,88 €
Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance
This European project consisted of the design of a diagnostic platform, its development and validation, as well as the mutational analysis of patients with chronic lymphocytic leukaemia, developing a new algorithm for the detection of copy number alterations (CNVs) and rearrangements from capture panel sequencing data.
-
Period: 2016-2019 -
Financing: 104.653,90 €
Collaboration with associations
At Dreamgenics we are committed to working to improve people's lives.
For this reason, we have signed agreements with several patient associations to promote the genetic diagnosis of their diseases, as well as to develop research projects and training activities related to them.
Academic and research collaborations
We have signed framework educational cooperation agreements for training, consulting and research activities with the Universidad Europea de Madrid and the Universidad CEU San Pablo.
Dreamgenics and CEU San Pablo University sign an educational cooperation framework agreement
Dreamgenics and CEU San Pablo University sign a framework educational cooperation agreement for the joint implementation of training activities for the...
Dreamgenics signs scientific-technological collaboration agreement with FINBA
The Foundation for Biosanitary Research and Innovation of Asturias (FINBA) and Dreamgenics have signed an institutional collaboration framework agreement to...
Dreamgenics signs a collaboration agreement with Universidad Europea
Dreamgenics has as a fundamental objective of its activity as a biotechnology company to collaborate in the development of Precision Medicine, and to achieve this...